This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
by Zacks Equity Research
Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 86.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Field Trip Health Ltd. (FTRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Molecular Templates Inc. (MTEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 98.3% in Molecular Templates Inc. (MTEM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?
by Zacks Equity Research
Molecular Templates Inc. (MTEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -115.38% and -50.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.